Idera Pharmaceuticals, Inc.(NASDAQ : IDRA)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
Loading IDRA News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-0.65%||69.85||1.0%||$924.33m|
|REGN||Regeneron Pharmaceuticals, Inc.||-0.49%||371.18||1.9%||$343.16m|
|ALXN||Alexion Pharmaceuticals, Inc.||-1.20%||128.82||2.0%||$287.09m|
|ARIA||ARIAD Pharmaceuticals, Inc.||0.00%||23.98||13.0%||$197.31m|
|CLVS||Clovis Oncology, Inc.||7.22%||65.80||16.4%||$141.36m|
|VRTX||Vertex Pharmaceuticals Incorporated||0.72%||88.33||2.6%||$140.89m|
|A||Agilent Technologies, Inc.||1.53%||51.62||1.7%||$115.01m|
|ACAD||ACADIA Pharmaceuticals Inc.||0.11%||39.26||19.0%||$90.91m|
Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which is engaged in discovery, development and commercialization of novel nucleic acid therapeutics to treat patients with serious and life-threatening diseases. The company uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates: Toll-like receptor targeting technology and third-generation antisense technology. Idera Pharmaceuticals was founded by Paul C. Zamecnik, Sudhir A. Agrawal and James B. Wyngaarden on May 25, 1989 and is headquartered in Cambridge, MA.